Bacterial vaginosis (BV) is the most common cause of vaginal discharge worldwide and is associated with significant stigma, health care utilization and antibiotic use. Recurrence rates exceed 50% within 6 months in most studies. Until recently data supporting partner treatment to prevent BV recurrence were lacking; however, a recent clinical trial showed a clear preventive benefit from the concomitant treatment of cis-gender male partners (with oral plus topical antibiotics) of individuals with BV, with a more than 60% reduction in BV recurrences. This presentation will outline the current understanding of BV as a dysbiosis, the role of sexual transmission in pathogenesis, and the recent findings of the Australian StepUp* Trial. Practical suggestions will be offered regarding designing and implementing a policy to provide partner therapy for BV in clinical settings in the United States based on the experience at a walk in public Sexual Health Clinic. Essential components include the need for clinician and staff education given the major change in health messaging regarding the role of sexual transmission in the pathogenesis of BV, and the practical difficulties related largely asynchronous visits of patients and partners who seek health care in different places, difficulties with pharmacy instructions, and the myriad of clinical scenarios that arise which were not addressed in the StepUp trial given strict inclusion/exclusion criteria.